The triggering receptor expressed on myeloid cells 2 (TREM2) plays a pivotal role in the activation of myeloid cells and is currently being investigated as a potential therapeutic target in several ...

JCR Pharmaceuticals has signed a licence agreement with Alexion, AstraZeneca Rare Disease, for its proprietary JUST-AAV ...

In July 2025, Novartis Pharmaceuticals conducted a Phase III multi-center, single dose (1.2 x 1014 vector genomes), ...

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...

Request To Download Free Sample of This Strategic Report @ This country research report on Vietnam Gene Therapy Market offers comprehensive insights into the market landscape, customer intelligence, ...

Monoclonal antibodies show strong therapeutic potential against neurodegenerative diseases, but a major challenge is ensuring ...

The collaboration will establish a platform for leukaemia and other cancer treatments within the Middle East and Africa.

Boston, MA – June 12, 2025 — Receptor.AI, a leading AI-driven drug discovery company, today announced the incorporation of the REAXENSE TM platform, developed by Reaxense Inc., a Canadian chemical and ...

Recent research has proposed several host factors required for SARS-CoV-2 infection and involved in the inflammatory response. Among these, members of the human serpin family and PAR2 have been ...

Bladder cancers (BCs) that invade the muscle layer are classified as muscle-invasive bladder cancers (MIBCs). The MIBC subtype accounts for around 25% of all BC cases, with a significant proportion of ...

The research team first induced an increase in CB1 receptor abundance in mouse astrocytes by developing a viral vector that contained the genetic material coding for the CB1 receptor as well as a ...